1 In cultured bovine adrenal chroman cells, NS-7 [4-(4-¯uorophenyl)-2-methyl-6-(5-piperidinopentyloxy) pyrimidine hydrochloride], a newly-synthesized neuroprotective drug, inhibited veratridine-induced 22 Na + in¯ux via voltage-dependent Na + channels (IC 50 =11.4 mM). The inhibition by NS-7 occurred in the presence of ouabain, an inhibitor of Na + ,K + ATPase, but disappeared at higher concentration of veratridine, and upon the washout of NS-7. 2 NS-7 attenuated veratridine-induced 45
Ca2+ in¯ux via voltage-dependent Ca 2+ channels (IC 50 =20.0 mM) and catecholamine secretion (IC 50 =25.8 mM). 3 Chronic (512 h) treatment of cells with NS-7 increased cell surface [ 3 H]-STX binding by 86% (EC 50 =10.5 mM; t 1/2 =27 h), but did not alter the K D value; it was prevented by cycloheximide, an inhibitor of protein synthesis, or brefeldin A, an inhibitor of vesicular transport from the trans-Golgi network, but was not associated with increased levels of Na + channel a-and b 1 -subunit mRNAs. 4 In cells subjected to chronic NS-7 treatment, 22 Na + in¯ux caused by veratridine (site 2 toxin), ascorpion venom (site 3 toxin) or b-scorpion venom (site 4 toxin) was suppressed even after the extensive washout of NS-7, and veratridine-induced 22 Na + in¯ux remained depressed even at higher concentration of veratridine; however, either a-or b-scorpion venom, or Ptychodiscus brevis toxin-3 (site 5 toxin) enhanced veratridine-induced 22 Na + in¯ux as in nontreated cells. 5 These results suggest that in the acute treatment, NS-7 binds to the site 2 and reversibly inhibits Na + channels, thereby reducing Ca 2+ channel gating and catecholamine secretion. Chronic treatment with NS-7 up-regulates cell surface Na + channels via translational and externalization events, but persistently inhibits Na + channel gating without impairing the cooperative interaction between the functional domains of Na + channels.